- Leukemia
- Liver Cancer
- Lung Cancer
- Lung Cancer – Non-Small Cell
- Lung Cancer – Small Cell
- Lymphoma
- Melanoma
- Mesothelioma
- Miscellaneous
- Multiple Myeloma
- Myelodysplastic Syndrome
- Neuroblastoma
- Non-Hodgkin’s Lymphoma
- Aggressive/Intermediate Grade Non-Hodgkin’s Lymphoma
- Follicular Lymphoma
- Highly Aggressive/High Grade Non-Hodgkin’s Lymphoma
- Indolent/Low Grade Non-Hodgkin’s Lymphoma
- Mantle Cell Non-Hodgkin’s Lymphoma
- Recurrent Non-Hodgkin’s Lymphoma
- Screening/Prevention Non-Hodgkin’s Lymphoma
- T-Cell Non-Hodgkin’s Lymphoma
- Osteosarcoma
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer
- Rectal Cancer
- Renal Cancer
- Retinoblastoma
- Sarcoma
- Skin Cancer
- Supportive Care
- Management and Prevention of Anemia Supportive Care
- Management and Prevention of Anorexia and Weight Loss Supportive Care
- Management and Prevention of Bone Complications Supportive Care
- Management and Prevention of Fatigue Supportive Care
- Management and Prevention of Mucositis Supportive Care
- Management and Prevention of Nausea and Vomiting Supportive Care
- Management and Prevention of Neutropenia Supportive Care
- Management and Prevention of Thrombocytopenia Supportive Care
- Testicular Cancer
- Throat Cancer
- Thyroid Cancer
- Uterine Cancer
- Vaginal Cancer
Cancer News
Vectibix® Improves Survival in Colorectal Cancer, Demonstrates Importance of Tissue Testing
(01/28/2016)
The addition of Vectibix® (panitumumab) to best supportive care improves survival over best standard care alone among colorectal cancer patients who have stopped responding to chemotherapy. However, the benefit is only seen with patients who have no RAS mutations, or those with only the KRAS exon 2 mutation. These results were recently presented at the … Continue reading "Vectibix® Improves Survival in Colorectal Cancer, Demonstrates Importance of Tissue Testing"